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This article describes a pharmacogenetic investi-gation of nicotine metabolism in twins. One
hundred and thirty-nine twin pairs (110 monozygotic
and 29 dizygotic) were recruited and assessed for
smoking status, zygosity, and health conditions
known or suspected to affect drug metabolism.
Participants underwent a 30-minute infusion of stable
isotope-labeled nicotine and its major metabolite,
cotinine, followed by an 8-hour in-hospital stay. Blood
and urine samples were taken at regular intervals for
analysis of nicotine, cotinine, and metabolites by gas
chromatography–mass spectrometry or liquid chro-
matography–mass spectrometry and subsequent
characterization of pharmacokinetic phenotypes. DNA
was genotyped to confirm zygosity and for variation
in the primary gene involved in nicotine metabolism,
CYP2A6. Univariate and multivariate biometric analy-
ses planned for the future will determine genetic and
environmental influences on each pharmacokinetic
measure individually and in combination with each
other, and in the presence and absence of covariates,
including measured genotype. When the analyses are
completed, this study will result in a more complete
characterization of the impact of genetic and environ-
mental influences on nicotine and cotinine metabolic
pathways than has heretofore been reported. The
approach taken, with its use of a quantitative model
of nicotine metabolism, highly refined metabolic phe-
notypes, measured genotype, and advanced tools for
biometric genetic analysis, provides a model for the
use of twins in next-generation studies of complex
drug-metabolism phenotypes.
The use of the twin design to study genetic contribu-
tions to variability in human drug response has a
history dating back to the early work of Luth (1939;
as cited in Weber, 1997) in which the heritability of
the plasma half-life of ethanol was estimated from
intraclass correlations in 10 pairs of monozygotic
(MZ) and 10 pairs of dizygotic (DZ) twins. From the
1950s through the early 1990s, the twin design was
used mainly as a strategy to screen for metabolic phe-
notypes with genetic variation in response to a variety
of drugs including the plasma half-life of ethanol
(e.g., Vesell et al., 1971), the plasma concentration of
lithium (Dorus et al., 1975), and per cent dose of
halothane metabolized (an anesthetic; Cascorbi et al.,
1971; studies reviewed in Weber, 1997). While these
studies typically involved fewer than 20 pairs of twins
of each zygosity, the broad heritability estimates of
various pharmacokinetic phenotypes ranged from a
low of 0.37 (halothane; Cascorbi et al., 1971) to a
high of 1.00 (isoniazid; an antibiotic; Bönicke &
Lisboa, 1957, as cited in Weber, 1997). Taken as a
whole, the body of evidence from the early twin
studies shows substantial genetic involvement in drug
metabolism. It is also apparent that the extant litera-
ture on pharmacology in twins has examined
relatively few pharmacokinetic indices of drug metab-
olism, has relied on very small samples of twins, and
has not used state-of-the-art techniques for quantifi-
cation of the relative contribution of genetic and
environmental influences. Additionally, nicotine meta-
bolic phenotypes have thus far not been investigated
in a genetically informative sample.
While nicotine is generally recognized as the single
most important compound involved in the processes
leading up to and maintaining tobacco dependence
(Stolerman & Jarvis, 1995), the relative contribution
of genetic and environmental influences to nicotine
metabolic pathways described by Benowitz and Jacob
(1997) is unknown. Although certain genes such as
P450 CYP2A6 are clearly implicated in relevant path-
ways for nicotine metabolism (Benowitz, Tyndale et
al., 2002; Messina et al., 1997; Nakajima et al.,
1996), a complete understanding of all relevant candi-
date genes (e.g., CYP2B6 [Yamazaki et al., 1999] and
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Quantitative scheme of nicotine metabolism.
Modified from Benowitz & Jacob (1997). Circled compounds are excreted in the urine; numeric values indicate the associated percent of systemic
dose of nicotine.
CYP2D6 [Caporaso et al., 2001; Cholerton et al.,
1994]) and their interactions in the pathways has not
yet been realized.
A separate, but nonetheless important, issue is the
relationship between variation in P450 genes and nico-
tine dependence. Polymorphism in CYP2A6, including
gene deletion, has been shown in some studies to be
associated with the likelihood of being a nonsmoker
(Ando et al., 2003; Iwahashi et al., 2004; Pianezza 
et al., 1998; Sellers et al., 2000; Tyndale & Sellers,
2001). However, the association has not been con-
firmed in other studies (Schulz et al., 2001; Zhang 
et al., 2001). A recent meta-analysis of all studies
reported to date concluded that there is not a consis-
tent association between variation in CYP2A6 and
smoking behaviors (Carter et al., 2004). Among the
possible reasons for inconsistent findings regarding
CYP2A6 are, firstly, variation across studies in statisti-
cal power, use of ethnically heterogeneous groups, use
of different genotyping assays, and different pheno-
typic definitions (Schoedel et al., 2004), or secondly,
that all the genetic variants active in the metabolic
pathway are incompletely described, thereby resulting
in an increased amount of unaccounted-for variance in
the metabolism-dependence association.
There are several reasons why understanding the
nature of individual differences in nicotine metabolism
is important. Variations in the pharmacokinetics of
nicotine could provide clues as to, first, why some
people go on to become regular users after initial
exposure to tobacco while others experience pro-
nounced adverse reactions and do not initiate regular
use (O’Loughlin et al., 2004; Pomerleau et al., 1993);
second, why some individuals smoke more heavily
than others; and third, why nicotine replacement
therapy is more effective in some but not other individ-
uals (Swan & Carmelli, 1997).
This article describes the convergence of two lines
of work that, until now, have evolved independently
of each other: (a) biometric genetic studies in twins
have demonstrated a significant role for genetic influ-
ences on tobacco use and nicotine dependence
(Carmelli et al., 1992; Heath & Madden, 1995;
Kendler et al., 1999; Lessov et al., 2004; Li et al.,
2003; McGue et al., 2000; Sullivan & Kendler, 1999;
Swan & Carmelli, 1997; True et al., 1999) and (b)
laboratory pharmacology studies have characterized
nicotine metabolic pathways (Benowitz & Jacob,
1997; see Figure 1), documented individual stability
over time in nicotine disposition and kinetics, and
reported substantial between-subject variability on
these parameters (Benowitz & Jacob, 1994; Benowitz,
Perez-Stable et al., 2002; Perez-Stable et al., 1998).
The purpose of the present article is to describe
the methodologies used to create and execute the
largest twin study of nicotine metabolism (and of any
drug) reported to date. We describe methods for
recruitment, screening, consenting, genotyping, bio-
logical sampling, and calculation of pharmacokinetic
parameters. We further describe planned biometric
analyses and conclude with a discussion of several
challenges and solutions encountered during the
course of this investigation.
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Methods
Setting
The study involved two primary research centers: the
Center for Health Sciences at SRI International,
California, USA, and the Division of Clinical
Pharmacology and Experimental Therapeutics,
University of California, San Francisco (UCSF), based
at the San Francisco General Hospital Medical
Center. SRI was responsible for the recruitment,
screening, and scheduling of twin pairs drawn from
the SRI Northern California Twin Registry (NCTR;
described below) and will be responsible for the
planned biometric analyses. UCSF was responsible for
conducting the nicotine/cotinine infusion procedure 
at San Francisco General Hospital (SFGH); for ana-
lytical chemistry procedures to determine nicotine,
cotinine, and metabolite levels; and for quantifica-
tion of pharmacokinetic parameters. Additional
contributions were made by the University of
Toronto, Department of Pharmacology (genotyping
for CYP2A6), and by the Department of Neurology,
UCSF (molecular determination of zygosity).
Participants
The NCTR was created in 1995 to fill the need for a
pool of twins for genetic studies of drug metabolism.
In 1996, an extensive advertising campaign was con-
ducted and included advertising in 19 newspapers, San
Francisco Bay area–wide movie theaters, and AM/FM
radio stations. Within 2.5 years, this campaign
resulted in the enrolment of a total of 1054 twins, a
large enough pool from which to recruit twins to the
present study. Contact was (and continues to be)
maintained with twins in the NCTR via annual
newsletters and birthday cards. In addition to the
above methods, a 5-year NCTR anniversary-celebra-
tion party held in July 2000 increased enrollment to
1765 individual twins. A NCTR website is maintained
(http://www.sri.com/policy/twin/) and referrals to the
NCTR by registered twins is encouraged. Currently,
there are over 2000 twins registered with the NCTR.
Recruitment and Enrollment Procedures
Exclusion Criteria
To minimize the effect of medical conditions and/or
medication usage known to influence metabolism,
individuals were excluded from participation if they
met any of the following criteria:
• age of less than 18 years or more than 65 years
• weight of more than 30% over ideal height-adjusted
weight
• pregnancy
• the presence of any of the following conditions:
— use of drug metabolism–altering medications
such as anticonvulsant drugs and barbiturates
— uncontrolled hypertension or diabetes
— a history of heart disease as indicated by self-
report or history of bypass surgery, valve
replacement, use of a pacemaker, or angioplasty
procedures
— Raynaud’s disease
— chronic diseases such as cancer, liver, and
kidney diseases, or asthma, that were not stable
or were not in remission for at least 1 year
— migraine headaches
— anemia
— abnormal blood-sugar levels that were not well
controlled by medication
— substance abuse and/or dependence
— psychiatric disorders that could limit study
compliance or require the use of metabolism-
altering psychotropic medications
— positive HIV status
— hepatitis B or C
— history of vasovagal reactions
— discomfort with venipuncture procedures, or a
self-reported history of ‘difficult veins’.
Because the study procedures could be seriously con-
founded or could lead to adverse events for the
participants by the presence of the conditions
described above, a three-tiered screening procedure
was employed (see below and Figure 2).
All methods for recruitment, informed consent,
screening, and data collection were reviewed and
approved by the Institutional Review Boards of SRI
International and UCSF.
Consent and Recruitment
At the initial telephone contact, verbal consent was
obtained prior to discussion of study details and col-
lection of information relevant to exclusion criteria.
Following verbal consent, participants were given 
a description of study procedures and protocol. 
To encourage participation, a variety of recruitment
incentives were described including the opportunity to
receive the results of the DNA-based zygosity analy-
sis; and $300 compensation for full participation in
the infusion and follow-up procedures. Additionally,
because the infusion procedures were designed in such
a way as to allow for simultaneous but independent
testing of both members of a twin pair, the opportu-
nity to participate with the co-twin over the course of
the hospital stay was also described.
Telephone Screen for Exclusionary Conditions
At the time of first contact and following verbal
consent to participate, detailed screening questions
were asked to determine eligibility as described above.
At this time, participants also provided information
required for admission to SFGH. A Phlebotomy
Screening Form was completed over the phone to
determine preferred time of day and location for
future phone contacts and appointments for blood
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Telephone recruitment of Twin 1 Twin 1 interested?
Telephone screen Twin 1 eligible?
MD review (if necessary) MD approval?
Both twins interested, eligible, and approved?
Informed consent of Twin 1 Twin 1 consents?
In-person screen Twin 1 eligible?
MD review (if necessary) MD approval?
Both twins consent, eligible, and approved?
Schedule Twin 1 for hospital visit
In-hospital screen Twin 1 eligible?
MD review (done for all) MD approval?
Both twins eligible and approved?
Initiate nicotine infusion































Repeat above process for Twin 2
Repeat above process for Twin 2
Repeat above process for Twin 2
Figure 2
Sequence of activities to recruit, screen, review, consent, schedule, and assess study participants.
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draws, study participation dates, and any relevant
information to facilitate future venipuncture proce-
dures. The completed form was sent to the project
physician for further review and an indication of
exclusion. If both twins met preliminary eligibility 
following phone screening, an appointment was
scheduled with a staff phlebotomist (see below), and a
tentative date for the infusion procedure set.
In-Person Screen for Exclusionary Conditions
Study participants were met at a location of their
choice (usually the home or place of employment) by
a phlebotomist. Following written consent to partici-
pate, detailed information about current medication
usage was collected. A minimum of two blood pres-
sure (BP) and heart rate (HR) readings were taken. 
A 30 ml blood sample was collected for biochemical
screening tests along with a urine sample to test for
pregnancy in female participants. Participants who
did not tolerate venipuncture well (due to a vasova-
gal reaction, etc.) were advised to reconsider their
participation in the study. Laboratory blood tests
included complete blood-cell counts; electrolytes;
kidney and liver function; hepatitis B and C; and
surface antigen, antibody, and nicotine and cotinine
concentrations.
Study participants who lived out of state or did
not reside in the San Francisco Bay area were directed
to a laboratory located near their place of residence 
to provide blood and urine samples. These results
were forwarded to the project manager for review.
Subsequent to receipt of study materials, a staff
member reviewed details of the consent form with the
participant over the telephone and answered any
questions about study procedures, risks, and benefits.
Participants who were uncertain about their typical
BP and HR readings were asked to have these mea-
sured by their own healthcare provider and to report
the readings to the project manager.
All participants who gave verbal consent to partic-
ipate in the study at the initial telephone contact and
screen were sent a questionnaire to more completely
assess health and smoking history, and use of recre-
ational substances. Participants who met initial
screening criteria were asked to bring their question-
naires to the second screening appointment. Those
who did not meet criteria were asked to return their
completed questionnaires via mail.
All laboratory blood results, BP, and HR readings
were subsequently reviewed by the project managers
and/or physician. If any laboratory results were not
within normal ranges, the participant was contacted
by the project physician and referred to another
healthcare provider when appropriate. Participants
who were deemed eligible after the in-person visit and
subsequent review of the clinical data were notified 
as such. The project recruiter then contacted both
members of a twin pair to confirm the previously
selected date for the infusion procedure.
In-Hospital Screen for Exclusionary Conditions
Participants were asked to arrive at SFGH by 7:00 a.m.
on the appointed day. They had been asked to abstain
from food and, if necessary, cigarette smoking from
10:00 p.m. the night prior to their appointment.
Immediately after their arrival, a resting 12-lead ECG
and BP and HR measures were obtained. These mea-
surements were again reviewed by the project physician
who also conducted a brief physical examination. The
clinical research associate then obtained anthropomet-
ric measurements to determine body composition
(% fat) and conducted several interviews focusing on
family history of smoking, ethno-cultural background,
and, for female participants, reproductive information.
Questionnaire Measures
Zygosity
Zygosity status was assessed by standard zygosity
questionnaire items (Cederlof et al., 1961) and con-
firmed by DNA genotyping (see below). Zygosity
questions included whether, as children, the twins
were ‘as alike as two peas in a pod’; whether parents,
siblings, or teachers had trouble telling them apart;
and the twins’ own knowledge of their zygosity.
Demographics
A series of standard questions were asked to deter-
mine date of birth, ethnicity, marital status, number
of children, and educational attainment.
General Health
In addition to information pertinent to the previously
described exclusionary conditions, participants also
provided a history of hospitalization for major
medical illness or surgery.
Menstrual Cycle
The timing of each female participant’s menstrual
cycle was determined following a previously 
published approach (Pomerleau et al., 1992). The
infusion protocol was scheduled to occur in the mid-
to late-follicular phase (operationally, between the
end of the menses and day 11 of the cycle).
Dietary Assessment
Regular consumption of some substances could possi-
bly influence drug metabolism (Ingelman-Sundberg,
2002). Therefore, a series of questions assessed the 
frequency and quantity of alcohol consumption,
including four questions from the Michigan Alcoholism
Screening Test (MAST; Cyr & Wartman, 1988), and
frequency and quantity of caffeinated beverages.
Individuals’ consumption of foods known to enhance
drug metabolism, such as broiled meats and cruciferous
vegetables (Conaway et al., 2002; Lampe & Peterson,
2002; Zhou et al., 2004), was also assessed.
Smoking History
A series of questions were asked to ascertain smoking
status (never, former, or current smoker). Among
respondents who reported they were current or
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former regular smokers, data were collected on age of
smoking initiation; years smoked; smoking topogra-
phy, including number of cigarettes smoked and depth
of inhalation; and nicotine dependence using the
Fagerström Test for Nicotine Dependence (FTND;
Heatherton et al., 1991). Potential sources of expo-
sure to environmental tobacco smoke were assessed in
all participants.
In-Hospital Pharmacokinetic Study Procedures
The project physician prepared the nicotine/cotinine
solution for all participants who attended SFGH for
the infusion appointment. Two factors determined the
nicotine dose level: body weight and preinfusion
plasma cotinine levels. Participants received 0.5
µg/kg/min if plasma cotinine levels were 50 ng/ml or
lower (levels consistent with not smoking or smoking
five or fewer cigarettes per day), 1.0 µg/kg/min if
plasma cotinine levels were 50–150 ng/ml (levels con-
sistent with smoking 5–15 cigarettes per day); and 2.0
µg/kg/min if plasma cotinine levels were > 150 ng/ml
(levels consistent with smoking 15 or more cigarettes
per day). The dose was always based on the lower
plasma cotinine level within a twin pair so that both
twins of pairs discordant for smoking received the
same dose.
In-dwelling catheters were placed in each arm. The
catheter in the right arm was used to deliver the stable
isotope-labeled nicotine/cotinine solution while the
catheter in the left arm was used to obtain periodic
blood samples.
Participants received a simultaneous intravenous
infusion of deuterium-labeled nicotine (nicotine-d2 =
3’, 3’-dideuteronicotine) and cotinine (cotinine-d4 = 2,
4, 5, 6-tetradeuterocotinine). Labeled compounds are
necessary for metabolic studies as individuals who use
tobacco already have considerable levels of nicotine
and cotinine in their bodies which would make 
measurement of clearance of unlabeled nicotine or
cotinine impossible. The synthesis of these deuterium-
labeled compounds and their preparation for infusion
has been described previously (Jacob et al., 1988).
During all infusions, participants underwent continu-
ous cardiac monitoring and frequent BP measurements
(described below).
Prior to the start of the 30-minute nicotine infu-
sion, baseline blood and urine samples were obtained
from each participant. After the start of the infusion,
a total of 10 blood samples (5 ml) were obtained at
the following intervals: 10, 20, 30, 45, 60, 90, 120,
180 minutes, and at 4 and 6 hours. All urine was col-
lected over the course of the 8-hour protocol. In order
to make the lengthy 8-hour stay in hospital as pleas-
ant as possible, participants were provided with
snacks, meals, a television and a video machine with a
large collection of popular movie videos.
Prior to discharge, posthospitalization blood-
sample collection procedures and appointment times
were reviewed with participants so that blood
samples (5 ml) could be obtained on four subsequent
consecutive mornings.
Pharmacokinetic Measures. Concentrations of
natural and deuterium-labeled nicotine and
cotinine in blood were measured by gas chromatog-
raphy–mass spectrometry (GC–MS) with the use of
nicotine–3’,3’–d2–N’–methyl–d2 (nicotine–d4) and
c o t i n i n e – 2 , 4 , 5 , 6 , 4 ’ , 4 ’ – d 6 – N ’ –
methyl–d3 (cotinine–d9) as internal standards (Jacob
et al., 1991). The limit of quantitation was 0.5 ng/ml
for nicotine and cotinine. Concentrations of nico-
tine–d2 and cotinine–d4 were corrected for the
presence of naturally occurring stable isotopes in
nicotine from tobacco.
Concentrations of deuterium-labeled nicotine and
metabolites in urine were measured using liquid chro-
matography–tandem mass spectrometry (analyses not
yet completed). Each assay measures nicotine, six
metabolites, and deuterium-labeled isoptomers (19
analytes in all; Jacob et al., 2002).
Glucuronide-conjugated nicotine, cotinine, and
trans–3’–hydroxycotinine were measured as the dif-
ference in total concentrations before and after
hydrolysis by incubation with beta-glucuronidase, as
described previously (Benowitz et al., 1999).
Standard pharmacokinetic parameters were esti-
mated from blood concentration and urinary-
excretion data using model-independent methods
described previously (Benowitz & Jacob, 1994; Perez-
Stable et al., 1998). Total clearances were computed as
CLnic-d2 = Dosenic-d2 / AUCnic-d2
CLcot-d4 = Dosecot-d4 / AUCcot-d4
where CL is clearance, AUC is area under the plasma-
concentration curve extrapolated to infinity, nic-d2 is
labeled dideuteronicotine, and cot-d4 is labeled
tetradeuterocotinine.
Renal clearances were calculated as urinary excre-
tion of nicotine or cotinine divided by AUC over 8
hours. Metabolic clearance was estimated as total
minus renal clearance.
Fractional conversion of nicotine to cotinine (f)
was estimated by using blood levels of cotinine gener-
ated from infused nicotine and the clearance of
cotinine itself, determined by infusion of cotinine:
f = AUCcot-d4 / Dosenic-d2 x CLcot-d4
The metabolic clearance of nicotine via the cotinine
pathway (CLnic→cot) was computed as CLnic-d2 × f.
Urine. We measured a number of nicotine metabolites
in the urine of the participants. In sum, these metabo-
lites account for an average of 90% of a dose of
nicotine. Nicotine, cotinine, nicotine–N–oxide, 
cotinine–N–oxide, trans–3’–OH–cotinine (3–HC),
and glucuronide conjugates of nicotine, cotinine, and
3–HC are expressed as a percentage of the dose of
nicotine administered (Benowitz et al., 1999).
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Pharmacodynamic Measures. BP and HR measures
were taken by an automated recording machine 15
times throughout the day in-hospital as follows: one
measure immediately prior to the start of the infu-
sion; at 5, 10, 15, 20, 25, and 30 minutes during the
infusion; and at 45, 60, 90, 120, and 180 minutes
and 4, 6, and 8 hours after the infusion. Cardiac
monitoring was performed continuously throughout
the period of infusion and for an additional 30
minutes postinfusion.
Genotyping for Zygosity
Self-reported zygosity was confirmed by genotyping
highly polymorphic microsatellite markers on 11
chromosomes (D1S1612, D2S1788, D3S1764,
D4S2368, D5S1501, D7S513, D8S1110, D13S1796,
D14S608, D16S753 and D15S657) using the method
described by Weber and May (1989).
Genotyping for CYP2A6
Genotyping of CYP2A6*12, CYP2A6*2,
CYP2A6*4, and CYP2A6*7 was performed accord-
ing to previously described protocols (Goodz &
Tyndale, 2002; Rao et al., 2000; Xu, Rao et al.,
2002). Methods to detect CYP2A6*9 and
CYP2A6*12 alleles are described elsewhere (Schoedel
et al., 2004). Each allelic assay relies on a two-step
polymerase chain reaction (PCR)–detection system,
where the first amplification uses genomic DNA as
the template with gene-specific primers and the
second amplification uses DNA derived from the first
PCR amplification with allele-specific primers. Taq
polymerase was obtained from Gibco BRL (Life
Technologies, Burlington, Canada) or MBI Fermentas
(Burlington, Canada). For the genotyping procedures,
each set of samples included three positive controls
with the different genotyping combinations and a
negative control lacking DNA. All PCR amplifica-
tions were performed using PTC-200 Peltier Thermal
Cyclers, and the second amplification products were
analyzed on 1.2% or 3% agarose gels (OnBio,
Richmond Hill, Canada) containing ethidium
bromide. A 1kb DNA ladder was used for each set of
samples to confirm the appropriate amplicon sizes.
Genotyping for variation in CYP2B6 and CYP2D6 is
underway and results will be reported at a later date.
Participant Process Measures
In order to assess any concerns or questions that par-
ticipants may have had during and following their
participation in the study, specific information on par-
ticipant reactions to all phases of the study was
obtained. For all phases of the study, participants
were asked for their suggestions for improving proce-
dures, whether they would recommend the study to
other twins, and whether they would participate in
future NCTR studies.
Results
A pool of 1054 twins from which to recruit for this
study was available. The nicotine infusion and biolog-
ical-sample collection protocol was completed suc-
cessfully in 278 (88.5%) of the 314 twins scheduled.
There were both medical and nonmedical reasons for
nonparticipation and failure to complete the entire
study (Figure 3). One hundred and ninety-two twins
(18.2%) refused participation for a variety of reasons,
including ‘fear of blood draws or needles’ (n = 23;
12%), ‘too busy’ (n = 56; 29%), ‘concern about
effects of nicotine’ (n = 33; 17%), or ‘other’ (n = 80;
42%). At the initial telephone screen, 542 twins
(51% of the total contacted) were deemed to be ineli-
gible for participation due to the presence of one of
the following conditions: health (n = 266; 49%),
being overweight (n = 125; 23%), ineligibility of the
co-twin (n = 114; 21%), or psychiatric condition 
(n = 38; 7%). At the in-person screen, an additional
6 twins were deemed to be ineligible due to blood
chemistry results (hepatitis; n = 3; 50%) or negative
reactions to venipuncture (n = 3; 50%). At the 
in-hospital appointment, 20 more twins were deter-
mined to be ineligible due to a history of severe
vasovagal reactions (n = 10; 50%), abnormal ECG (n
= 6; 30%), elevated BP (n = 2; 10%), or negative
reaction to the infusion (n = 2; 10%). In all, 561
(53.3%) twins were determined to be ineligible for
participation in this investigation. Sixteen twins
(5.1% of the 314 twins scheduled) failed to arrive for
their in-hospital appointment.
Characteristics of Eligible and Ineligible Twins
Table 1 compares demographic, health, and smoking
characteristics between infusion-protocol ineligible (n
= 548) and eligible twins (n = 314). These groups
were similar with respect to zygosity, sex, educational
attainment, smoking status, use of alcohol, use of pre-
scription medications, and fainting history. Relative to
ineligible twins, eligible volunteers were younger
(36.1 vs. 40.8 years; p < .01), more likely to be
married or living with someone (54.4% vs. 45.8%; p
< .05), and were more ethnically diverse (21.7% vs.
15.6% nonwhite; p < .05). Among nonwhite study
participants, 14.7% were African American, 52.9%
were Hispanic, 20.6% were Asian, and 11.8% were
‘other’. Given the extensive exclusion criteria, relative
to those who were eligible, ineligible twins were more
likely to be greater than 30% overweight (14.6% vs.
0.6%, p < .01) and have higher rates of hypertension
(12.3% vs. 2.6%; p < .01), heart disease (5.7% vs.
0.3%; p < .01), diabetes (4.0% vs. 1.3%; p < .05),
and psychiatric conditions (12.8% vs. 5.8%; p < .01).
Pharmacokinetic Parameters in Study Sample
Complete data for pharmacokinetic phenotypes were
ultimately available from a total of 138 complete twin
pairs. For one twin of an additional MZ male–male
pair (total n = 139 twin pairs), nicotine clearance data
were not available due to technical problems. The
sample, by zygosity, comprised 75 MZ female and 34
MZ male same-sex twin pairs; 19 DZ female and 4
441Twin Research October 2004
Nicotine Metabolism in Twins
https://www.cambridge.org/core/terms. https://doi.org/10.1375/twin.7.5.435
Downloaded from https://www.cambridge.org/core. IP address: 136.56.14.111, on 05 Feb 2021 at 20:08:06, subject to the Cambridge Core terms of use, available at
DZ male same-sex twin pairs; and 6 DZ female–male
twin pairs.
Table 2 shows the means of eight weight-adjusted
CL, volume of distribution (Vss) parameters, as well as
nicotine and cotinine half-life (t1/2) measures, sepa-
rately for MZ and DZ twins. Means were compared
across zygosity groups, adjusting for nonindepen-
dence of data in twin pairs, as well as for age, sex,
current smoking, and use of medications, where
appropriate (StataCorp, 2001). MZ and DZ twins did
not significantly differ in mean metabolic parameters.
In advance of planned multivariate biometric
analyses, Table 3 shows MZ and DZ twin-pair
Pearson correlation coefficients between metabolic
measures. In MZ twins, overall, metabolic measures
in one twin significantly correlated with metabolic
measures in the cotwin, suggesting that covariation in
metabolic phenotypes may be, in part, due to familial
(genes plus shared environment) factors. In contrast,
in DZ twins, most cross-twin cross-phenotype corre-
lations were not significant. Significant correlations in
MZ but not in DZ twins suggests that covariation
among metabolic parameters may be largely due to
genes rather than to shared environmental factors.
CYP2A6 Genotype Frequencies
In a subset of twins, each of whom was randomly
selected from a pair with genotypic data, the following
allele frequencies were observed: wild-type alleles
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Table 1
Comparison of Ineligible with Eligible Study Participants
Characteristics Ineligible Eligible
n = 548 n = 314
Age, mean (SD) 40.8 (13.8) 36.1 (12.0)**
Zygosity (self-reported), % DZ 29.7 29.0
Gender, % female 72.2 70.4
Education, % > high school 73.6 78.2
Marital status, % married or
cohabiting 45.8 54.4*
Ethnicity, % nonwhite 15.6 21.7*
Smoking status, %
ever smoke 44.3 39.0
currently smoke 18.6 16.6
> 30% overweight, %a 14.6 0.6**
Screening Questionnaire n = 228b n = 314
Drink alcohol, % yes 72.8 79.9
Prescription meds, % yes 55.9 48.2
Hypertension history, % yes 12.3 2.6**
Coronary heart disease history, 5.7 0.3**
% yes
Diabetes history, % yes 4.0 1.3*
Other illness, % yes 19.9 9.3**
Psychiatric disorder, % yes 12.8 5.8**
Ever fainted, % yes 33.3 33.1
Note: a If respondent was more than 30% overweight, screening was terminated.
b If a twin was ineligible for any reason, the co-twin was not screened.
*p < .05, **p < .01.
Table 2
Pharmacokinetic Parameters (Means ± SD) in MZ and DZ Zygosity
Groups
Pharmacokinetic measures MZ twin pairs DZ twin pairs
(n = 110) (n = 29)
CLnic-d2 , mL/min/kg 18.0 ± 6.2 17.8 ± 6.2
Vss nicotine, L/kg 2.5 ± 0.7 2.4 ± 0.6
t1/2 nicotine, min 119 ± 41 113 ± 34
f 0.75 ± 0.13 0.77 ± 0.14
CLnic→cot , mL/min/kg 13.7 ± 5.9 14.0 ± 6.2
CLcot-d4 , mL/min/kg 0.72 ± 0.36 0.74 ± 0.36
Vss cotinine, L/kg 1.0 ± 0.3 1.0 ± 0.3
t1/2 cotinine, min 1080 ± 348 1045 ± 363
Note: CLnic→cot = rate of enzyme activity computed as nicotine clearance (CLnic-d2;
mL/min/kg) multiplied by the conversion ratio of nicotine to cotinine (f); Vss =
steady-state volume of distribution (L/kg); t1/2 = half-life (min).
Table 3
Cross-Twin Cross-Phenotype Correlations for Pharmacokinetic Parameters in MZ Twins (n = 110 pairs; above the diagonal) 
and DZ Twins (n = 29 pairs; below the diagonal)
Twin 2 Twin 1
CLnic-d2 Vss nic t
1/2 nic f CLnic→cot CLcot-d4 Vss cot t
1/2 cot
CLnic-d2 — .33** –.45** .21** .61** .41** .33** –.36**
Vss nic .14 — .07 .01 .25** .09 .17* –.06
t1/2 nic –.11 .22 — –.26** –.44** –.35** –.21** .36**
f .12 .09 –.03 — .39** .06 .04 –.23**
CLnic→cot .16 .12 –.08 .13 — .34** .30** –.35**
CLcot-d4 –.11 –.15 –.05 .11 –.07 — .32** –.35**
Vss cot –.13 –.23 –.10 .06 –.10 –.16 — .03
t1/2 cot –.02 –.09 –.11 –.06 .01 –.07 .48** —
Note: CLnic→cot = rate of enzyme activity computed as nicotine clearance (CLnic-d2 ; mL/min/kg) multiplied by the conversion ratio of nicotine to cotinine (f); Vss = steady-state volume of
distribution (L/kg); t1/2 = half-life (min). Twin-pair Pearson correlation coefficients were computed in SAS using double-entered data.
*p < .05, **p < .01; correlation is significantly different from zero.
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(including *1A and *1B; n = 231, 84.31%), *12
alleles (n = 5, 1.82%), *2 alleles (n = 6, 2.19%), *4
alleles (n = 7, 2.55%), *9 alleles (n = 17, 6.20%), *12
alleles (n = 8, 2.92%). These frequencies are similar to
those reported previously for a sample of unrelated
individuals of European descent (Schoedel et al., 2004).
Participant Process Responses
During the course of the study, 124 participants pro-
vided feedback concerning their experiences with
study activities via telephone interviews. Sixteen per
cent of the participants reported unusual or unex-
pected discomfort caused by the blood draws during
the screening phase and 14% reported discomfort
during the 4-day follow-up, largely attributable to
residual soreness related to the use of in-dwelling
catheters in both arms during the previous in-hospital
infusion. When asked if they would recommend the
study to other twins, 97% said ‘Yes’. Ninety-nine per
cent said they would be willing to participate in
future NCTR studies.
Discussion
Execution of the methods described in this article led
to the creation of the largest study of drug metabo-
lism in twins reported to date. The method of recruit-
ment, screening, in-hospital and follow-up assessment
resulted in the collection of state-of-the-art metabolic
phenotypes that will be, in turn, subjected to bio-
metric genetic analysis to estimate the relative
contribution of genetic and environmental factors in
univariate and multivariate models. One objective is
to determine the range of magnitude of heritability
estimates on individual metabolic phenotypes.
Another objective is to estimate the extent to which
the same genetic factors account for covariation
among the various metabolic measures. This will be
important information for the eventual mapping of
the genetic architecture of these complex traits. The
presence of both males and females affords the oppor-
tunity to determine the extent to which sex is an
important contributor to the observed cross-twin and
cross-phenotype covariances. Finally, the fact that all
participants were genotyped for variation in CYP2A6
(and are being genotyped for CYP2D6 and CYP2B6)
will make it possible to incorporate genotype into the
biometric models of metabolism, an approach
intended to take full advantage of the unique dataset
acquired over the course of this investigation (van den
Oord et al., 2004; van den Oord & Sneider, 2002).
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Generalizability of the Study Sample
The characteristics of the NCTR and participant
samples were similar with regard to gender and
zygosity. However, most likely as a result of the
method of recruitment for the NCTR, both samples
had an overrepresentation of females and MZ twins.
This situation is similar to other twin studies which
have relied on recruitment through the media, and
largely reflects a bias in the nature of volunteers for
research (Lykken et al., 1987).
The overall rate of nonwhite participation in this
study is below the 2000 United States Census estimate
(http://factfinder.census.gov) for nonwhites residing in
the San Francisco Bay area (41.3%), and increasing
participation among nonwhites in research studies, 
in general, remains a serious issue (Britton et al.,
1999; Seto, 2001). The rate of current smoking in
study participants (16.6%) is lower than the national
median prevalence (23.1%; Centers for Disease
Control, 2004) and most likely reflects the effects of
the California tobacco-control campaign, one of the
most aggressive smoking-reduction programs in the
United States (Pierce et al., 1998). On the other hand,
the percentage of participants reporting consumption
of alcohol (79.9%) is somewhat higher than that
reported for the California population (65.1%;
Centers for Disease Control, 2000).
Pharmacokinetic parameter means in MZ and DZ
twins are comparable to those published in previous
studies using the same methodology for computing
metabolic parameters but different samples of women
and men of European descent (Benowitz, Perez-Stable
et al., 2002; Perez-Stable et al., 1998). Consistency
across studies validates the measurement of nicotine
metabolic phenotypes, which may represent more bio-
logically relevant phenotypes to understanding tobacco
use and nicotine dependence (Swan et al., 2003).
Planned Biometric Analyses
Genetic analysis will be conducted in univariate
context in which variance in a single phenotype will
be examined, or in multivariate context in which the
covariance among two or more metabolic phenotypes
will be examined. In the univariate approach, we will
determine the heritability of all nicotine pharmacoki-
netic parameters, numerous smoking measures, as
well as HR and BP and their change over the course
of the nicotine infusion protocol. We will also investi-
gate whether pharmacokinetic parameters are under
the combined influence of the same, overlapping, or
distinct genetic and environmental factors. This latter
approach will be especially important in gaining a
better understanding of the heterogeneity of factors
that influence nicotine metabolic phenotypes. Finally,
all biometric models will be examined for goodness-
of-fit in the absence and presence of covariates such
as age, gender, BMI, and CYP2A6 genotype. With the
completion of genotyping of the remaining two P450
genes, indicator variables for the three genotypes and
their interactions will be included in advanced bio-
metric models to determine whether this additional
information further increases goodness-of-fit.
Study Limitations
Limited Number of DZ Twin Pairs. The number of
DZ twin pairs recruited to this study was lower than
anticipated. Nonetheless, given our sample size, and
assuming no significant contribution from shared
environmental sources, we will have more than 80%
power to detect genetic effects of 30% or greater in
univariate analysis of the continuous pharmacokinetic
phenotypes. In preliminary univariate genetic analyses
in a subset of twins, we found evidence for substantial
heritability (66.3%) of the weight-adjusted nicotine
clearance parameter (Swan et al., 2001). We will have
sufficient power for bivariate genetic analysis (i.e.,
estimating the genetic correlation between pairs of
metabolic phenotypes, or between metabolic and cig-
arette-smoking phenotypes). Specifically, we will be
able to detect a genetic correlation of .5 as long as
each of the two measured phenotypes have heritabil-
ity estimates of 35% or greater. We will, however, be
underpowered for modeling sex effects.
Lack of Ethnic Variation
The results from this investigation will be generaliz-
able to individuals of European descent. There are
reasons to believe that the relative frequencies of inac-
tive variants responsible for nicotine metabolism may
well be different in individuals of other ethnicities.
For example, individuals of Chinese descent are
known to have a higher prevalence of CYP2A6 vari-
ants associated with slower nicotine metabolism
(Oscarson et al., 1999, 2002; Xu, Goodz et al.,
2002), and this is reflected in lower levels of mea-
sured total and nonrenal CL of nicotine and cotinine
and CLnic→cot, as well as in lower rates of daily number
of cigarettes smoked (Benowitz, Perez-Stable et al.,
2002). Variation among racial groups also exists in
other nicotine metabolic pathways such as nicotine
and cotinine glucuronidation (Benowitz et al., 1999).
This suggests that additional differences in the rates
of nicotine metabolism among racial groups may be
due to variation in the frequencies of allelic variants
in genes responsible for nicotine-N-1-oxidation (i.e.,
flavin containing monooxygenase 3 gene; Cashman et
al., 1995) and glucuronidation (i.e., UDP-glucuronyl-
transferase genes; de Leon, 2003; Nakajima et al.,
2002). For these reasons, we plan to pursue a twin
study of nicotine metabolism in other racial popula-
tions in the near future (e.g., Yang et al., 2002).
Complexity of the In-hospital Infusion Protocol
Most detailed studies of nicotine metabolism in the
past have relied on the intravenous administration 
of nicotine with multiple blood and urine samples 
for measurement of nicotine and metabolites. The
complexity of the exclusion criteria and subsequent
logistical requirements resulted in far fewer eligible
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twin volunteers than we might otherwise have had for
this study. In order to reduce complexity and enhance
participant acceptance of metabolic investigations, we
recently developed a novel way to study nicotine
metabolism using the oral administration of small
doses of deuterium-labeled nicotine and cotinine, with
measurement of blood, saliva, and urine concentra-
tions of nicotine and metabolites (Dempsey et al., in
press). We have utilized this new approach in a small
sample of twins and have found acceptance to be
much higher, especially for individuals of non-
European descent.
The Potential Impact of Violations 
of the Equal Environment Assumption
The twin method relies on the assumption that trait-
relevant environmental influences contribute equally
to the resemblance of MZ and DZ twin pairs (Pam et
al., 1996). Environmental influences that are more
similar for MZ compared to DZ twin pairs may be
associated with a metabolic phenotype and could
account for greater similarity between MZ than DZ
twins (i.e., inappropriately inflating estimates of heri-
tability). One way to address possible violations in
the equal environment assumption is to test whether
MZ and DZ twins differ in aspects that may affect
nicotine metabolism (e.g., diet) and test whether such
differences are associated with differences in MZ
compared to DZ twin-pair similarity on nicotine-
metabolism measures.
Conclusions
A number of unanticipated challenges were encoun-
tered throughout this study that were largely a
function of the complexity of the exclusion criteria and
the inherent difficulty associated with processing
related individuals through concurrent procedural
steps. Both members of a twin pair were required to
agree to participate and to meet eligibility require-
ments. Therefore, recruitment efforts failed with some
twin pairs due to inability to reach consensus regarding
participation or the ineligibility of one of the co-twins.
Participants were further required to be available
to meet with a staff phlebotomist by 1 p.m. on the
following 4 consecutive days in order to obtain
postinfusion blood samples. The rate of successful
collection of these samples was enhanced when these
samples were obtained at a time and place that was
convenient for participants. In order to anticipate par-
ticipant travel during the 4-day postinfusion interval,
blood tubes and shipping supplies were provided at
the time of the infusion. Arrangements were then
made for traveling participants to provide blood
samples at laboratory facilities convenient to their
destination, as necessary.
The twins themselves played a key role in the
success of this study through their exceptional interest
and commitment to the study. Despite their busy
schedules (85% were in the work force and 46% had
young children), twins agreed to devote a minimum
of 16 hours to study appointments along with the
time involved in numerous recruitment, screening,
and appointment-setting and appointment-confirma-
tion telephone calls. By doing so they have made a
critical contribution to the largest-ever twin study of
drug metabolism. Subsequent analyses of this impor-
tant resource will shed further light on genetic and
environmental variation in nicotine metabolism in its
entire complexity.
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